300
Participants
Start Date
March 20, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
Vedolizumab (VDZ)
Participants will receive VDZ as part of routine care.
Ustekinumab (UST)
Participants will receive UST as part of routine care.
Risankizumab (RISA)
Participants will receive RISA as part of routine care.
RECRUITING
University of North Carolina, Chapel Hill
RECRUITING
Digestive and Liver Center of Florida, Kissimmee
RECRUITING
University of Iowa, Iowa City
ACTIVE_NOT_RECRUITING
Northwestern University, Evanston
RECRUITING
University Medical Center New Orleans, New Orleans
ACTIVE_NOT_RECRUITING
GI Alliance Research Mansfield, Mansfield
ACTIVE_NOT_RECRUITING
GI Alliance Research Fort Worth, Fort Worth
NOT_YET_RECRUITING
GI Alliance - Sun City, Sun City
RECRUITING
OR Clinic - East - GI, Portland
ACTIVE_NOT_RECRUITING
GI Alliance - Bellevue - Washington Gastroenterology, Bellevue
RECRUITING
University of Alberta, Edmonton
RECRUITING
University of British Columbia, Vancouver
RECRUITING
GNRR Digestive Clinics and Research Center, Brampton
RECRUITING
Alimentiv, London
RECRUITING
West GTA Research Inc., Mississauga
RECRUITING
Rajbir Rai Medicine Professional Corporation, Oakville
RECRUITING
ABP Research Services Corp., Oakville
RECRUITING
Scarborough Center for Inflammatory Bowel Disease, Scarborough Village
RECRUITING
Toronto Immune & Digestive Health Institute Inc., Toronto
RECRUITING
McMaster University Medical Center, Hamilton
Lead Sponsor
Collaborators (1)
Takeda
INDUSTRY
Alimentiv Inc.
OTHER